72F fusion protein

From Wikipedia, the free encyclopedia

This article or section has multiple issues. Please help improve the article or discuss these issues on the talk page. It does not cite any references or sources. Please help improve it by citing reliable sources. Tagged since March 2008. It needs to be expanded. Tagged since March 2008. Sections should be added to this article, to conform with Wikipedia's Manual of Style. Tagged since March 2008. Its introduction may need to be rewritten to comply with Wikipedia's lead section guidelines. Tagged since March 2008.

72F fusion protein is a candidate tuberculosis vaccine created by SSI. The 72F fusion protein is composed of the Rv0125 and Rv1196 proteins derived from Mycobacterium tuberculosis. Phase I clinical trials were completed in 2005 and Phase II trials are awaited.

[edit] See also

• Fusion protein

[edit] References

• Kaufmann SHE, McMichael AJ (2005). "Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis". Nature Med 11 (4 suppl): S33–S44. doi:10.1038/nm1221. PMID 15812488.